Novo Nordisk Kazakhstan LLP is a affiliate of the global pharmaceutical company Novo Nordisk A/S, founded in 1923 in Denmark, shortly after the discovery of insulin by Canadian scientists in 1921. Novo Nordisk is the world market leader in the treatment of diabetes and is also a leader in the areas of hemostasis management, growth hormone therapy and obesity. Our focus is on the serious chronic diseases that affect hundreds of millions of people and are among the most urgent global health challenges.By combining our innovation and commercial excellence, we draw upon insights from patients and partners to transform bold ideas into life-saving and preventive medicines.
Novo Nordisk Kazakhstan
- Chief:Rana Azfar Zafar, VP & GM